Pictured: Two business professionals in suits shaking hands/iStock, fizkes

图为：两位身着西装的商务专业人士握手/伊斯托克，菲兹克斯

Massachusetts-based Orna Therapeutics announced on Thursday it is acquiring competing RNA biotech ReNAgade Therapeutics. The terms of the acquisition were not disclosed.

总部位于马萨诸塞州的Orna Therapeutics周四宣布，它正在收购竞争对手RNA biotech ReNAgade Therapeutics。收购条款未披露。

ReNAgade launched in 2023 with $300 million in Series A financing, aiming to deliver RNA medicines to inaccessible cells and tissues. The biotech combines several delivery technologies with gene insertion, coding and editing tools. In January, ReNAgade was named to BioSpace’s NextGen Bio Class of 2024 life sciences startups to watch this year..

ReNAgade于2023年启动，获得了3亿美元的A系列融资，旨在向无法进入的细胞和组织提供RNA药物。该生物技术将多种传递技术与基因插入，编码和编辑工具相结合。1月，ReNAgade被提名为生物空间2024生命科学初创公司的NextGen Bio类，今年将观看。。

Orna, which is focused on designing circular RNA therapeutics and was named to BioSpace’s NextGen Bio Class of 2022, said in Thursday’s announcement that ReNAgade is a “pioneer” in “unlocking the potential” of this technology. ReNAgade has “demonstrated industry-leading delivery” displayed positive delivery to multiple extra-hepatic cells in non-human primate models over the past 18 months, according to the press release..

Orna专注于设计环状RNA疗法，并被命名为2022年BioSpace的NextGen生物类，在周四的公告中表示，ReNAgade是该技术“释放潜力”的“先驱”。据新闻稿称，在过去18个月里，ReNAgade在非人灵长类动物模型中“展示了行业领先的分娩”，显示出对多个肝外细胞的阳性分娩。。

ReNAgade CEO Amit Munshi will take over as the CEO of Orna, succeeding Tom Barnes, who will remain on the board of directors and chair the scientific advisory board.

ReNAgade首席执行官阿米特·蒙西（AmitMunshi）将接替汤姆·巴恩斯（TomBarnes）出任Orna首席执行官，汤姆·巴恩斯将继续担任董事会成员和科学顾问委员会主席。

“RNA-centric approaches are poised to eclipse traditional cell therapy-based methods and reshape the future of medicine,” Munshi said in a statement. “This strategic acquisition unifies Orna’s and ReNAgade’s strengths and capabilities under one roof, expanding technological synergies and multiplying the companies’ depth and breadth of expertise to drive a unique RA therapeutic-focused R&D engine.”.

Munshi在一份声明中说：“以RNA为中心的方法有望超越传统的基于细胞疗法的方法，重塑医学的未来。”。“这项战略性收购将Orna和ReNAgade的优势和能力统一在一个屋檐下，扩大了技术协同作用，并扩大了公司的专业知识深度和广度，以推动一个独特的以RA治疗为重点的研发引擎。”。

Munshi added that Orna’s circular RNA technology will be combined with ReNAgade’s portfolio of lipid nanoparticle-based RNA delivery systems and editing programs. Together, they will have a “robust” pipeline with panCAR programs in autoimmune diseases and oncology, genetic disease programs and a vaccine program partnered with Merck.

Munshi补充说，Orna的环状RNA技术将与ReNAgade的基于脂质纳米颗粒的RNA递送系统和编辑程序组合相结合。他们将在自身免疫性疾病和肿瘤学、遗传疾病项目以及与默克公司合作的疫苗项目方面与panCAR项目建立一个“强大”的渠道。

In 2022, Orna and Merck inked a potential $3.5 billion partnership to explore the development of vaccines and other therapeutic programs with Orna’s technology. .

2022年，Orna和默克公司签署了一项价值35亿美元的潜在合作协议，以探索利用Orna的技术开发疫苗和其他治疗方案。。

“The combination of technologies positions Orna to advance best-in-class panCAR in vivo CAR RNA therapies and expand existing gene editing delivery solutions with circular RNA to address the massive unmet need in multiple diseases,” Barnes said in a statement.

巴恩斯在一份声明中说：“这些技术的结合使Orna能够推进同类最佳的panCAR体内CAR RNA疗法，并用环状RNA扩展现有的基因编辑递送解决方案，以解决多种疾病中大量未满足的需求。”。

Orna launched in 2021 with a $100 million Series A and secured a $221 million Series B a year later. Its technology is built on research from Daniel Anderson’s lab at MIT. The company’s tech is a synthetic circular RNA with a structure designed to overcome production and performance challenges associated with RNA. .

Orna于2021年推出了价值1亿美元的a系列，一年后获得了价值2.21亿美元的B系列。它的技术基于麻省理工学院丹尼尔·安德森实验室的研究。该公司的技术是一种合成的环状RNA，其结构旨在克服与RNA相关的生产和性能挑战。

Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

泰勒·帕肯（Tyler Patchen）是BioSpace的一名全职作家。你可以通过tyler.patchen@biospace.com.在LinkedIn上关注他。